Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neuroimaging effects of a single dose of modafinil on brain activation in patients with schizophrenia: a randomised controlled trial

Trial Profile

Neuroimaging effects of a single dose of modafinil on brain activation in patients with schizophrenia: a randomised controlled trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Modafinil (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics
  • Acronyms Newmeds 2
  • Most Recent Events

    • 07 Jan 2015 Accrual to date is 176% according to United Kingdom Clinical Research Network record
    • 03 Dec 2014 Accrual to date is 173% according to United Kingdom Clinical Research Network record
    • 23 Oct 2014 Accrual to date is 161% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top